[CTSO] Cytosorbents Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 5.5 Change: 0.1 (1.85%)
Ext. hours: Change: 0 (0%)

chart CTSO

Refresh chart

Strongest Trends Summary For CTSO

CTSO is in the long-term down -64% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -29.46% Sales Growth - Q/Q-17.28% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-82.35% ROE-135.15% ROI
Current Ratio2.4 Quick Ratio2.29 Long Term Debt/Equity Debt Ratio0.64
Gross Margin53.09% Operating Margin-233.51% Net Profit Margin-345.24% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10.01 M Cash From Investing Activities-1.13 M Cash From Operating Activities-2.41 M Gross Profit420 K
Net Profit-4.72 M Operating Profit-2.71 M Total Assets15.86 M Total Current Assets14.88 M
Total Current Liabilities6.2 M Total Debt Total Liabilities6.2 M Total Revenue720 K
Technical Data
High 52 week12.64 Low 52 week4.25 Last close4.58 Last change3.15%
RSI36.8 Average true range0.34 Beta1.73 Volume10 K
Simple moving average 20 days-7.78% Simple moving average 50 days-8.17% Simple moving average 200 days-31.7%
Performance Data
Performance Week-3.17% Performance Month-17.48% Performance Quart-36.83% Performance Half-34.85%
Performance Year-57.43% Performance Year-to-date-43.32% Volatility daily4.4% Volatility weekly9.84%
Volatility monthly20.17% Volatility yearly69.86% Relative Volume219.85% Average Volume183.35 K
New High New Low

News

2020-05-27 12:00:00 | CytoSorbents Announces Virtual Annual Meeting

2020-05-19 08:03:00 | CTSO: Q1 2020: CTSO Nabs FDA breakthrough designation and European approval for ticagrelor removal, Q1 Product revenue sets new record, Moving PT to $15/share

2020-05-12 07:08:00 | CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery

2020-05-08 14:24:00 | The Charts of Cytosorbents Suggest We Might See Further Gains Ahead

2020-05-06 15:01:33 | Cytosorbents Corp CTSO Q1 2020 Earnings Call Transcript

2020-05-05 16:15:00 | CytoSorbents Reports First Quarter 2020 Financial and Operational Results

2020-05-04 07:08:00 | CytoSorbents Promotes Vincent J. Capponi to President

2020-04-28 08:00:00 | CytoSorbents to Report Q1 2020 Operating and Financial Results

2020-04-27 07:08:00 | Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer

2020-04-20 06:58:00 | Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery

2020-04-15 07:00:00 | New Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome ARDS on ECMO

2020-04-13 15:31:00 | Coronavirus update: 1.89 million cases worldwide, 118,304 deaths; and Trump attacks Dr. Fauci and the New York Times

2020-04-13 11:44:00 | CytoSorbents Gains Emergency Authorization for Covid-19 Treatment

2020-04-13 11:44:00 | Coronavirus update: 1.87 million cases worldwide, 116,052 deaths; and Trump attacks Dr. Fauci and the New York Times

2020-04-13 10:06:00 | CytoSorbents' stock jumps on FDA authorization for its device in COVID-19 patients

2020-04-13 10:06:00 | CytoSorbents' stock jumps on FDA authorization for its device in COVID-19 patients

2020-04-13 07:43:00 | U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection

2020-04-03 12:06:00 | CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb® Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today

2020-03-31 07:08:00 | CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care

2020-03-30 16:23:32 | Cytosorbents’ Blood Purification Technology Could Play Important Role in Fighting COVID-19; Analyst Says ‘Buy’

2020-03-25 07:19:00 | CytoSorb® Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama

2020-03-12 09:33:00 | CytoSorbents Provides Update on CytoSorb and COVID-19 Coronavirus Activities

2020-03-05 16:15:00 | CytoSorbents Announces 2019 Financial and Operational Results

2020-03-05 14:45:00 | CytoSorbents Corp. to Host Earnings Call

2020-03-02 07:00:00 | CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits

2020-02-28 07:00:00 | CytoSorb Shipment Arrives in Designated Mainland China Hospitals to Treat Cytokine Storm in Critically-ill Patients with COVID-19 Coronavirus Infection

2020-02-19 07:00:00 | CytoSorbents Enters Agreement with China Medical System Holdings Limited to Bring CytoSorb to Mainland China to Treat Critically-ill Patients with COVID-19 Coronavirus Infection

2020-02-05 07:51:00 | CytoSorb Used Successfully to Help Treat Grade 4 Cytokine Release Syndrome Following CAR T-cell Immunotherapy in First Published Case Report

2020-02-02 08:25:10 | Analysts See 20% Upside to These 3 “Strong Buy” Tech Stocks

2020-01-29 07:25:00 | CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.

2020-01-29 06:38:45 | Introducing Cytosorbents NASDAQ:CTSO, The Stock That Dropped 41% In The Last Five Years

2020-01-28 07:01:00 | CytoSorb, the Wuhan Coronavirus, and Cytokine Storm

2020-01-22 06:30:00 | CytoSorb Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin

2020-01-14 09:30:00 | CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter

2020-01-10 16:11:26 | 2 Healthcare Stocks Set to Rally into the New Year

2020-01-07 10:13:00 | CytoSorbents to Present at Biotech Showcase™ 2020

2019-12-20 17:02:37 | Is Cytosorbents Corporation CTSO A Good Stock To Buy?

2019-12-11 05:23:08 | Trade Alert: The CEO, President & Director Of Cytosorbents Corporation NASDAQ:CTSO, Phillip Chan, Has Just Spent US$59k Buying Shares

2019-12-02 07:45:00 | CytoSorbents to Present at the Piper Jaffray 31st Annual Healthcare Conference

2019-11-25 07:00:00 | CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study

2019-11-19 07:00:00 | CytoSorbents to Present at the Three Part Advisors 2019 Southwest IDEAS Investor Conference

2019-11-06 17:15:00 | Dr. Eric Mortensen to Leave CytoSorbents At Year End

2019-11-05 16:15:00 | CytoSorbents Reports Third Quarter 2019 Financial Results

2019-11-05 05:52:17 | Is Cytosorbents NASDAQ:CTSO Using Too Much Debt?

2019-11-04 07:05:00 | CytoSorbents Announces Additions to its International Clinical Team

2019-11-01 07:15:00 | CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom

2019-10-30 07:30:00 | CytoSorbents to Report Q3 2019 Operating and Financial Results

2019-10-22 08:12:00 | CytoSorbents Awarded Approximately $3.0 Million by the U.S. Air Force to Advance Development of the K+ontrol System to Treat Severe Hyperkalemia

2019-10-15 08:00:00 | MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019

2019-10-11 06:59:13 | Is Cytosorbents Corporation's NASDAQ:CTSO CEO Salary Justified?